Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Cetuximab in Advanced Squamous Cell Carcinomas of Skin
NCT02324608Completed
- Sponsor
- Rutgers University
- Start
- Jan 2015
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of KL-140 in squamous cell carcinoma of the skin (SCC), sponsored by Rutgers University. Primary endpoint: Objective Response Rate at 2 years. Started Jan 2015; status: completed.
02
Drugs
KL-140
03
Conditions
squamous cell carcinoma of the skin (SCC)
Beyond the preview
Go deeper on NCT02324608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02324608.